The value and challenges of improving adherence to antiretroviral therapy for human immunodeficiency virus

Medical Care

Volumn 44, Issue 10, 2006, Pages 891-892

  Johnson, Mallory O ^a   Chesney, Margaret A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ECONOMICS; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION;

EID: 33748996489     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000242130.51174.9a     Document Type: Editorial

References (15)

1. Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44:893-899.
2. Fogarty L, Roter D, Larsen S, et al. Patient adherence to HIV medication regimens: a review of published and abstract reports [review]. Patient Educ Couns. 2002;46:93-108.
3. Rueda S, Park-Wyllie L, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006;19:CD001442.
4. Simoni JM, Frick PA, Pantalone DW, et al. Antiretroviral Adherence Interventions: A Review of Current Literature and Ongoing Studies. Top HIV Med. 2003;11:185-198.
5. Cote JK, Godin G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int J STD AIDS. 2005;16:335-343.
6. Simoni JM, et al. Efficacy of Interventions in Improving Highly Active Antiretroviral Therapy Adherence and HIV-1 RNA Viral Load: A Meta-Analytic Review of Randomized Controlled Trials. J AIDS Human Retrovirol. In press.
7. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285-297.
8. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
9. DHHS, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; 2006.
10. Trotta MP, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S128-S131.
11. Barnett E, et al. Promoting cardiovascular health: from individual goals to social environmental change. Am J Prev Med. 2005;29(5 Suppl 1):107-112.
12. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41:315-322.
13. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. Aids. 2006;20(2):p. 223-231.
14. Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr. 2005;40:106-109.
15. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:54-62.